{"id":"W3135098376","doi":"10.1016/j.annonc.2021.02.017","title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":292,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Topotecan; Internal medicine; Clinical endpoint; Ovarian cancer; Tolerability; Oncology; Population; Hazard ratio; Chemotherapy; Chemotherapy regimen; Progression-free survival; Cancer; Randomized controlled trial; Surgery; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004769877,0.0001765479,0.002716452,0.0003416428,0.00001410187,0.000002504846,0.00006950204,0.0001353053,0.0004041914],"category_scores_gemma":[0.000122329,0.0001334359,0.0003795332,0.0009080002,0.0001771852,0.00004094459,0.00002096763,0.00009344493,2.13082e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001346936,"about_ca_system_score_gemma":0.0009104059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008114397,"about_ca_topic_score_gemma":0.0006573072,"domain_scores_codex":[0.9979849,0.0001939519,0.0009729627,0.0002925624,0.0003424661,0.0002131033],"domain_scores_gemma":[0.9977128,0.0005329628,0.0007425348,0.0003480091,0.0005817176,0.00008200246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9324721,0.01417462,0.004011392,0.00007444015,0.01013353,0.00004464722,0.0003873013,0.00004421502,0.0003388188,0.0001236233,0.0002465794,0.03794874],"study_design_scores_gemma":[0.9512763,0.01614858,0.02134376,0.0001185983,0.00369535,3.202015e-7,0.0000427722,0.00005489952,0.006455848,0.00002540037,0.0007388185,0.0000993323],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929359,0.0007658775,0.00003684205,0.003058135,0.0001478274,0.001112725,0.0002230528,0.000005447867,0.001714199],"genre_scores_gemma":[0.997061,0.001147052,0.0009282472,0.000372619,0.00004005351,0.0001020691,0.0002911518,0.00001611936,0.00004165228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0378494,"threshold_uncertainty_score":0.5441356,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03864959317361016,"score_gpt":0.3720440515617144,"score_spread":0.3333944583881043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}